IPO OFFER SUMMARY
Size of the issue: The Company is offering a minimum of 1,581,722 and a maximum of 2,636,204 Units consisting of an equal number of Offer Shares and IPO Warrants, corresponding to gross proceeds between DKK 9.0 to 15 million from the Offering.
Price pr. unit: DKK 5,69 (consisting of one Offer Share and one IPO Warrant)
Valuation (pre-money): DKK 40 million
Subscription period: 17-30 September, 2021
Preliminary first day of trading: 7 October, 2021
Minimum subscription: 700 units
Listing on Nasdaq First North GM: Prior to the Offering, the Shares have not been publicly traded. The Company has applied for admission to trading of all Shares and the IPO Warrants on Nasdaq First North Growth Market Denmark (“First North Growth Market”) under the ticker “BRAINP”. First day of trading of the Shares (Permanent ISIN: DK0061670205) and the IPO Warrants (ISIN: DK0061670551) is expected to be on 7 October, 2021. All Shares will have the same rights and will rank pari passu in every respect.
Co-founder & CEO
Shares before the IPO: 2 533 500
Former Vice President of Marketing & Strategy @ world’s largest wind energy co. 5 years @ Boston Consulting Group. M.Sc. Management of Technology, CBS Cognitive Psychology studies, UCPH. Healthcare Innovation degree HARVARD Business School (Pasteur Program).
Chief Commercial Officer
Shares before the IPO: 170 152
15 years of experience leading teams in commercial excellence at Novo Nordisk, LEO Pharma and Sandoz. Commercial Lead for the EU launch of the first in-licensed digital therapeutic at Sandoz.
MA Political Economy, M.Sc. Public Health
Chief Science & Innovation Officer
12 years of experience as a biomedical engineer.
Experience from several medtech startups
Senior scientist & team mgr. at Coloplast.
Postdoc, Cognitive Neuroscience, University of Copenhagen.
PhD. Cognition and psychophysics, DTU.
Bertil Stengaard Jessen
Chief Financial Officer
Former head of a global strategic investment program at GN Store Nord. Corporate strategy and M&A advisory at Maersk and J.P. Morgan’s investment banking division.
MSc in Economics and Business Administration – Applied Economics and Finance from Copenhagen Business School.
Business Development Manager
Entrepreneur in public health care and digital health with successful exit of his company in Autism & dementia care software.
25 years experience in selling into public and private health care sectors.
Chief Technology Officer
10+ years in Software Development, 7 years in Pharma. Formerly Head of Digital Technologies at Lundbeck. Tech nerd and team manager. One of Berlingske’s Top 100 Talent in Denmark. MSc in Computer Science from University of Copenhagen. Co-founded health tech companies FindZebra and Healthy Mind Tech.
HELLE BEHRNDTZ JENSEN
Many years of financial management experience from the insurance and the venture industry. In-depth experience in preparation and execution of business plans and strategic management, and in supporting the business with strong gov- ernance and financial procedures.
BOARD OF DIRECTORS
Joined as chairman from H1 2021
Shares before the IPO: 678 306
Senior Partner, Nordic Capital
13 years in Private Equity, 14 years Head of Boston Consulting Group Denmark. Lars is an international heavy weight within business, strategy and economics.
Board Member since Sep 2018
Shares before the IPO: 40 000
Digital health and therapuetics entrepreneur, Co-founder & Chief Innovation Officer at Practio, Doctor of Medicine from University of CPH. Innovation Management, Harvard Business School.
HANNE LETH HILLMAN
Board Member since May 2021
Experienced life science executive focused on finance, communications and investor relations (IR). Additionally brings strong board experience. Currently the CFO for Nanovi A/S.
Keswick Global AG
A 1120 Vienna, Austria
+43 1 740 408045